CSIMarket
 


Revolution Medicines Inc   (RVMD)
Other Ticker:  
 

Cumulative Revolution Medicines Inc 's Quick Ratio for Trailing Twelve Months Period

RVMD's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

RVMD Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -59.57 % -53.12 % -4.91 % 2.71 % 41.2 %
Y / Y Cash & cash equivalent Growth 24.15 % 97.1 % 75.38 % 11.76 % 7.62 %
Quick Ratio for Trailing Twelve Months Period 18.62 14.2 10.54 8.9 8.69
Total Ranking # 176 # 197 # 254 # 379 # 431
Seq. Current Liabilities Growth -0.53 % -45.49 % -11.86 % -15.4 % 15.32 %
Seq. Cash & cash equivalent Growth -10.59 % -0.03 % 41.07 % -1.54 % 41.95 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Revolution Medicines Inc Cash & cash equivalent average grew by 24.15% in III. Quarter year on year, while Current Liabilities decreased to $ 30 millions, this led to increase in in Revolution Medicines Inc 's Quick Ratio for Trailing Twelve Months Period to 18.62, Quick Ratio for Trailing Twelve Months Period remained below Revolution Medicines Inc average.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry just one company has achieved higher Quick Ratio for Trailing Twelve Months Period. While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about RVMD
Quick Ratio RVMD in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 2
Sector # 17
S&P 500 # 30


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
12.6 10.05 1.65
(Sep 30 2021)   (Mar 31 2020)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Pharmacyte Biotech Inc   33.46 
Vaxcyte Inc   30.41 
Vigil Neuroscience Inc   29.82 
Prokidney Corp  28.76 
Cullinan Oncology Inc   22.90 
Graphite Bio Inc   20.25 
Hillevax Inc   19.33 
Cortexyme Inc   19.20 
Vor Biopharma Inc   18.84 
Acumen Pharmaceuticals Inc   18.27 
Cabaletta Bio Inc   17.82 
4d Molecular Therapeutics Inc   17.50 
Neumora Therapeutics Inc   17.50 
Tourmaline Bio Inc   17.35 
Krystal Biotech Inc   16.73 
Icosavax Inc   16.69 
Replimune Group Inc   16.58 
Protara Therapeutics Inc   15.84 
Apogee Therapeutics inc   15.75 
Fusion Pharmaceuticals Inc   15.74 
Revolution Medicines Inc   15.53 
Aura Biosciences Inc   15.21 
Genenta Science S p a   14.82 
Creative Medical Technology Holdings Inc   14.62 
Compass Therapeutics Inc   14.35 
Crispr Therapeutics Ag  13.99 
Anavex Life Sciences Corp   13.65 
Kymera Therapeutics Inc   13.35 
Voyager Therapeutics Inc   12.73 
Achilles Therapeutics Plc  12.56 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com